Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

SeaStar Medical Q3 Revenue Rises 247% to $635,000

None

SeaStar Medical Holding Corporation (ICU) reported third-quarter 2026 net revenue of $635,000, up 247% from $183,000 a year earlier. The company recorded a net loss of $4.5 million, or $1.03 per basic and diluted share, compared with a $3.5 million loss, or $1.30 per share, in the prior-year quarter.

Cash totaled $4.0 million at September 30, 2026. SeaStar said this balance excludes $3.3 million in gross proceeds from warrant exercises completed in October.

  • Third-quarter gross profit was $587,000, compared with $169,000 a year earlier.
  • Research and development expense was $3.6 million, while general and administrative expense was $1.6 million.
  • The NEUTRALIZE-AKI pivotal trial enrolled 251 of its planned 339 patients, or nearly 75%.
  • The company submitted the first module of its modular premarket approval application to the FDA for SCD therapy in adult AKI patients receiving CRRT.
  • SeaStar expects the NEUTRALIZE-AKI trial to complete enrollment by mid-year 2027.

$ICUCW Hedge Fund Activity

We have seen 6 institutional investors add shares of $ICUCW stock to their portfolio, and 1 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles